Biopharma Sustainability: Multilateral Guidance on Strategy, Opportunity, and Risk

In March 2022, the Biopharma Sustainability Roundtable (BRST) published an expanded resource for strategic thinking and planning of biopharma-investor ESG communications. The outcome of an ongoing dialog facilitated by the BSRT, the “Biopharma Investor ESG Guidance 4.0” document reflects a biopharma-investor consensus on the sector’s priority ESG topics and offers recommendations on what and resources for how biopharma companies can most effectively communicate with investors about ESG strategy, governance, risks, opportunities, and performance.  The Guidance 4.0 offers a shared sector-specific point of reference for biopharma ESG practitioners, investors and their representatives, policymakers, and standard-setters. This expert panel will discuss best practices in communicating ESG performance in a biopharma context and how sustainability discussions can become senior management opportunities to create value, beyond the existing and expanding set of regulatory reporting requirements.